Introduction
Approximately 40% of human breast cancers require estrogens such as 17b-estradiol for growth (Melora et al., 1998) . In the absence of estrogens or the presence of antiestrogens, proliferation of these tumor cells is inhibited and they accumulate in the G 1 phase of the cell cycle (Sutherland et al., 1983a,b) . Because of their ability to inhibit proliferation, antiestrogens are often used to treat breast cancer patients. However, a signi®cant proportion of tumors that initially respond to antiestrogen therapy eventually progress to a resistant state in which cell proliferation is no longer dependent on estrogens or inhibited by antiestrogens. Understanding the molecular mechanisms by which estrogens and antiestrogens regulate passage from G 1 to S phase, and those by which cells become antiestrogen resistant, are therefore important goals that may lead to improvements in breast cancer diagnosis and treatment.
Transit through G 1 into S phase is regulated by cyclin dependent kinases (CDKs), a family of protein kinases that are activated by association with cyclins. The CDKs that regulate passage through G 1 include CDK4 and CDK6, which are activated by the D-type cyclins, and CDK2, which is activated by both cyclin E and cyclin A (Sherr, 1993 (Sherr, , 1994 . One important target of G 1 cyclin/CDK complexes is the tumor suppressor protein pRb (Kato et al., 1993) . In its hypophosphorylated form, pRb associates with members of the E2F family of transcription factors, and prevents transcription of genes required for entry into S phase. Upon phosphorylation of pRb, E2F transcription factors are released and activate target genes that promote S phase entry ( Figure 1a ) (Hatakeyama and Weinberg, 1995; Nevins et al., 1997) .
The eects of estrogen and antiestrogen treatments on cell cycle progression have primarily been investigated in the MCF-7 cell line, which is an estrogen receptor positive human breast cancer cell line. Proliferation of MCF-7 cells is estrogen-dependent and antiestrogen sensitive both in vitro and in vivo (Osborne et al., 1985; Soule and McGrath, 1980; Sutherland et al., 1983a) , and in the presence of antiestrogens these cells accumulate in G 1 . Estrogen treatment of G 1 -arrested MCF-7 cells induces S phase entry, and this induction is associated with increases in cyclin D1 protein levels, cyclin D1/CDK4 kinase activity, CDK2 kinase activity, and pRb phosphorylation (Foster and Wimalasena, 1996; Planas-Silva and Weinberg, 1997; Prall et al., 1997; Watts et al., 1995) . In addition, overexpression of cyclin D1 in the presence of antiestrogens leads to pRb phosphorylation, and is sucient to promote proliferation for at least one cell cycle (Pacilio et al., 1998; Prall et al., 1998) .
One explanation for the ®ndings outlined above is that pRb is the ultimate target of the proliferative eects of estrogen, and that overexpression of cyclin D1 promotes proliferation in the presence of antiestrogens by increasing pRb phosphorylation via the activation of cyclinD1/CDK4 complexes. However, it is also possible that functions of cyclin D1 other than activating CDK4 contribute to or are responsible for antiestrogen resistance. For example, regulation of cyclin E/CKD2 kinase activity by estrogen and antiestrogens occurs in the absence of changes in cyclin E or CDK2 protein levels. To account for this observation, it has been proposed that induced or overexpressed cyclin D1 protein binds and sequesters the CDK inhibitor p21 cip1 , leading to activation of cyclin E/CDK2 complexes (Planas-Silva and Weinberg, 1997; Prall et al., 1997) . Another potential mechanism of cyclin D1 action is via its interactions with cellular transcription factors. Cyclin D1 binds to and modulates the activity of several transcription factors, including the estrogen receptor (Neuman et al., 1997; Zwijsen et al., 1997) and a myb-like transcription factor DMP1 (Hirai and Sherr, 1996; Inoue and Sherr, 1998) , and either of these activities could have profound eects on cell proliferation.
If pRb is the ultimate target of the proliferative eects of estrogen, one would predict that inactivation of this tumor suppressor protein would be sucient to confer antiestrogen resistance to MCF-7 cells. Alternatively, if functions of cyclin D1 other than promoting pRb phosphorylation are critical for its eects on estrogen dependence, then inactivation of pRb would not be sucient to promote antiestrogen resistance. To directly test the eect of pRb inactivation on antiestrogen sensitivity, we have expressed the simian virus 40 (SV) or polyoma virus (Py) large T antigens (LTs) in MCF-7 cells. Both SV-LT and Py-LT bind to and inactivate pRb (Brodsky and Pipas, 1998; DeCaprio et al., 1988; Larose et al., 1991; , thereby allowing E2F to activate transcription and promote S phase entry (Figure 1b) . SV-LT has several other activities in addition to pRb-binding, including the ability to inactivate the tumor suppressor protein p53 (Lane and Crawford, 1979; Linzer and Levine, 1979) . Py-LT shares most of these properties, but diers from SV-LT in that it does not bind to p53 (Brodsky and Pipas, 1998; Cole, 1996) . Using wild type and mutant forms of the viral proteins, we demonstrate that expression of either SV40 or polyoma virus LT is sucient to confer antiestrogen resistance to MCF-7 cells. This eect is dependent upon an intact pRb binding domain, but does not require a p53 binding domain. These data establish that pRb or a related protein is an important functional target of estrogen, and suggest that inactivation of normal pRb function could play a role in the development of antiestrogen resistance during tumor progression in vivo.
Results

Inhibition of DNA synthesis by antiestrogens in MCF-7 cells
Antiestrogens inhibit proliferation of MCF-7 cells. This is demonstrated in Figure 2a , in which the percentages of cells incorporating BrdUrd into DNA are compared in cultures incubated in basal medium containing 5% charcoal stripped serum (CSS), and in this medium supplemented with 17b-estradiol (E), 4-hydroxytamoxifen (TAM) or ICI 182 780 (ICI). As previously reported by others, the dependence of MCF-7 cell proliferation on exogenous E in cell culture is not absolute (Lippman et al., 1976; Sutherland et al., 1983a; Wakeling et al., 1991) . E stimulated proliferation, but there was considerable BrdUrd incorporation in the basal medium in these assays. TAM is a nonsteroidal antiestrogen with both agonist and antagonist activities. It acted as an antagonist in these assays, and decreased proliferation below the level observed in CSS alone. ICI is a steroidal antiestrogen with no agonist activity. As previously reported, it was a more potent inhibitor of MCF-7 cell proliferation than TAM (Wakeling et al., 1991) , and decreased the percentage of cells incorporating BrdUrd to approximately 3 ± 5%. In addition, MCF-7 cell derivatives that are resistant to ICI are cross-resistant to TAM, while TAM r cells are often sensitive to ICI (Brunner et al., 1993 (Brunner et al., , 1997 . The ability of a treatment to confer ICI resistance is therefore likely to also confer TAM resistance, while the converse is not true. For these reasons, ICI was the antiestrogen used in the remainder of our experiments.
Expression of SV40 large T antigen confers antiestrogen resistance to MCF-7 cells, and the pRb binding function is required for this effect
To determine the eect of SV-LT expression on antiestrogen sensitivity, plasmids encoding either wild type or mutant SV-LT proteins were introduced into MCF-7 cells, and the ability of the transfected cells to incorporate BrdUrd into DNA in the presence of ICI was determined as described in Materials and methods. SV-LT is a multifunctional protein that interacts with a number of cellular proteins, including the pRb family (pRb, p107, p130), p53, p300 and TBP (Brodsky and Pipas, 1998; Cole, 1996) . The mutants used in these experiments (Table 1) were defective in one or more of these activities that seemed likely to play a role in promoting antiestrogen resistance. As described in Materials and methods, none of the constructs encoding SV-LT were capable of replicating extrachromosomally, and any BrdUrd incorporation detected therefore represented cellular DNA replication.
Representative micrographs of cells expressing SV-LT and/or incorporating BrUrd are shown in Figure 3 . The percentages of SV-LT positive and SV-LT negative cells in each transfected culture that were also BrdUrd positive was determined, and the results of this analysis Figure 2b . The percentage of SV-LT negative cells that incorporated BrdUrd in the transfected cultures (3 ± 5%) was similar to untransfected, ICI treated controls (Figure 2a, b) , indicating that the transfection protocol did not cause proliferation. In contrast, cells expressing wild type SV-LT incorporated BrdUrd at a level comparable to the cycling (E) population. These results indicate that SV-LT is able to completely overcome an ICI-mediated cell cycle arrest in this assay.
The PVU1 mutant is defective in binding to pRb family members. In the presence of ICI, cells expressing PVU1 protein incorporated BrdUrd to the same low extent as untransfected cells (Figures 2b and 3 ). Both the transfection eciency of the PVU1 construct, and the level of expression of PVU1 protein in transfected cells were equivalent to the wild type (Figure 2c ), indicating that the defect in this mutant was not due to a failure of the protein to be expressed. We therefore conclude that the pRb-binding domain of SV-LT is absolutely required to overcome an ICI induced cell cycle arrest.
Two SV-LT mutants defective in p53 binding were also examined. One (2809) contains an insertion of four amino acids at position aa409, and the second (T1 ± 259) is a truncation mutant encoding the ®rst 259 amino acids of the protein. Both the 2809 and T1 ± 259 mutants were 60 ± 70% as eective as wild type SV-LT at inducing proliferation in the presence of ICI ( Figure  2b ). To investigate potential reasons for this small, but reproducible decrease in the ability of these mutants to overcome an ICI-induced arrest, both the transfection eciency of the DNA constructs and the level of expression of the encoded proteins in transfected cell populations were examined. As shown in Figure 2c , the percentage of cells expressing detectable SV-LT in 2809 and T1 ± 259 transfected cultures was approximately twofold lower than with the wild type, although the intensity of staining in LT positive cells was not detectably dierent between the three constructs. In agreement with these observations, overall T1 ± 259 protein levels in transfected cultures were approximately twofold lower than wild type as determined by Western blots. Interestingly, cultures containing the 2809 mutant expressed very low levels of full length LT protein, although they incorporated BrdUrd with approximately the same eciency as T1 ± 259. However, it was noted that 2809-transfected cells expressed relatively high levels (equal to that of the T1 ± 259 mutant) of a small protein of approximately 20 ± 25 kDa. Since the antibody used in these Western blots recognizes an N-terminal epitope of SV-LT (Harlow et al., 1981) , the 20 ± 25 kDa peptide may be an Nterminal fragment that retains the pRb binding domain and has activity in proliferation assays. Alternatively, all of the proliferative activity of the 2809 mutant may be due to the small amount of full-length protein present in the transfected cells. In summary, two dierent SV-LT mutants that are defective for p53 binding were able to induce proliferation in ICI treated MCF-7 cells. However, the magnitude of the eect was signi®cantly less than that seen with the wild type protein. Due to dierences in the levels of expression of the encoded proteins, the data obtained did not allow us to distinguish whether the decreased ability of the 2809 and T1 ± 259 mutants to overcome an antiestro- Reversal of antiestrogen sensitivity by T antigens H Varma and SE Conrad gen-induced arrest was due to decreased expression of these proteins, or if they were truly less active than wild type SV-LT.
Inactivation of p53 does not confer antiestrogen resistance
To further investigate the possibility that p53 inactivation played a role in SV-LT's ability to confer antiestrogen resistance, we examined the ability of Py-LT to promote proliferation of ICI-arrested MCF-7 cells. Py-LT binds to pRb, but does not bind or inactivate p53 (Brodsky and Pipas, 1998; Cole, 1996) . A plasmid encoding wild type Py-LT (pCMVLT) was transfected into MCF-7 cells, and proliferation was assayed in the presence of ICI as described above.
Representative¯uorescence micrographs are shown in Figure 3 , and summaries of the experiments are shown in Figures 2b and 4 . Although the average induction of proliferation was slightly lower than seen with SV-LT, the dierence was not statistically signi®cant. These results therefore indicate that Py-LT is as ecient as SV-LT in overcoming an antiestrogen-mediated arrest of MCF-7 cells, and establish that p53 inactivation is not required for this eect. The results presented above indicated that p53 inactivation was not required to confer antiestrogen resistance to cells under conditions where pRb family members were inactivated. To examine the eects of p53 inactivation alone on antiestrogen sensitivity, a plasmid encoding del239, a dominant negative (dn) p53 mutant (Gao et al., 1996) , was transfected into MCF-7 cells. Expression of this protein did not increase BrdUrd incorporation above that seen in untransfected cells (Figure 4 ). In addition, del239 expression did not enhance the level of proliferation induced by Py-LT alone in co-transfection experiments. We therefore conclude that p53 inactivation alone is not sucient to confer antiestrogen resistance, and that it does not enhance the resistance conferred by pRb inactivation, in MCF-7 cells.
Py-LT confers antiestrogen resistance in long term assays
It was previously reported that over-expression of cyclin D1 conferred antiestrogen resistance to MCF-7 cells in short term assays, but was not sucient to promote long term growth in the presence of antiestrogen (Pacilio et al., 1998) . We therefore wanted to determine if LT expression was sucient to confer antiestrogen resistance to MCF-7 cells in long term proliferation assays. Constructs encoding either a wild type or pRb binding mutant (dl141) of Py-LT were introduced into MCF-7 cells using the pneo-LT1 vector, which contains a G418 r gene for selection of stably transfected cells. Individual G418 r colonies were selected, expanded into cell lines, and tested for expression of Py-LT protein by Western blotting. Two cell lines expressing the wild type protein (WT1 and WT5) and one expressing the pRb binding mutant (dl 141) were chosen for further analysis (Figure 5a) . One G418 r cell line that did not express detectable levels of Py-LT protein (WT4), was used as a negative control. All of these cell lines grew well in the presence of 5% FBS, and contained similar amounts and ratios of hyper-and hypo-phosphorylated pRb in this medium (Figure 5a ).
The eects of ICI treatment on proliferation of the Py-LT expressing cells were evaluated in several ways. In Figure 5b , pRb phosphorylation and cyclin A expression were examined by Western blotting after 2 days of ICI treatment. Previous studies have shown that both pRb phosphorylation and cyclin A expression are inhibited by ICI treatment of the parental MCF-7 cell line (Watts et al., 1995) . In agreement with this, hyperphosphorylated pRb and cyclin A protein LT-encoding plasmids, incubated in medium containing ICI, and labeled with BrdUrd as described in Materials and methods. SV-LT was detected using a rhodamine-conjugated secondary antibody (red¯uorescence), and BrdUrd incorporation with an FITC-conjugated secondary antibody (green¯uorescence). Py-LT was detected using an FITC-conjugated secondary antibody, and in this case BrdUrd incorporation was detected with a rhodamine-conjugated secondary antibody. Overlay images were generated to show nuclei that were positive for both LT and BrdUrd, which appear yellow in the photograph 
Discussion
Previous evidence linking estrogen and antiestrogen treatments to pRb phosphorylation suggested that pRb might be a crucial target of estrogen, and that inactivation of this tumor suppressor protein might lead to antiestrogen resistance. We tested this possibility by expressing viral T antigens in MCF-7 cells, and determining their eects on antiestrogen sensitivity. Expression of either the SV40 or polyoma virus large T antigen promotes MCF-7 cell proliferation in the presence of the pure antiestrogen ICI 182,780. Furthermore, this eect is dependent upon the ability of the viral proteins to bind and inactivate pRb, but is independent of their ability to bind p53. Thus, pRb is an important target of estrogens in regulating MCF-7 cell proliferation, and its inactivation can contribute to the development of antiestrogen resistance.
The fact that both pRb inactivation and overexpression of cyclin D1 (Pacilio et al., 1998; Prall et al., 1998) promote MCF-7 cell proliferation in the presence of antiestrogens con®rms an important role for the cyclin D/pRb pathway in estrogen dependence. It also suggests that the primary mechanism by which cyclin D1 overcomes an antiestrogen-mediated arrest is by activating CDK 4/6, which in turn phosphorylate pRb. As discussed previously, CDK2 activity is inhibited in antiestrogen treated MCF-7 cells, and it has been proposed that a second role for cyclin D1 in promoting antiestrogen resistance is to sequester p21 cip1 , thereby leading to CDK2 activation. The results reported here suggest that either antiestrogen treatment fails to inhibit CDK2 activity in MCF-7 cells expressing T antigens, or that the requirement for CDK2 activity is bypassed in these cells. Since p21 cip1 transcription is induced by p53 (el-Deiry et al., 1993) , one mechanism by which SV-LT could lead to CDK2 activation would be by binding and inactivating p53, leading to decreases in p21 cip levels. However, this does not appear to play a role in promoting antiestrogen resistance, since LTs that do not inactivate p53 induce proliferation in the presence of ICI, and since a dn p53 mutant does not induce proliferation in the presence of ICI. The mechanisms by which LTs overcome the inhibition of CDK2 activity by antiestrogens therefore remain to be elucidated.
Although our results clearly demonstrate that an intact pRb-binding domain is required, they do not establish if pRb inactivation alone is sucient to confer antiestrogen resistance to MCF-7 cells. The Rb family also contains the related proteins p107 and p130. We cannot eliminate a role for p107 and/or p130 inactivation in conferring antiestrogen resistance, since both SV-LT and Py-LT bind these proteins, and since r clone that did not express detectable Py-LT, and served as a negative control. Hyperphosphorylated pRb (ppRb) migrates more slowly than the hypophosphorylated form (pRb) on these gels. (b) Cell lines were plated in medium containing 5% FBS, treated with either ICI (+) or vehicle (7) for 48 h, and cell extracts were prepared and analysed for pRb phosphorylation and cyclin A expression by Western blotting. The blots were also probed for actin as a control for protein loading Figure 4 Eects of Py-LT and dominant negative p53 expression on ICI sensitivity in MCF-7 cells. MCF7 cells were transfected with plasmids encoding Py-LT, a dn p53 (del239), or both. BrdUrd incorporation in the presence of ICI was determined in Py-LT or del239 positive cells (®lled bars) and Py-LT or del239 negative cells (open bars), and is expressed as a percentage of the total cells. BrdUrd incorporation was also measured in cycling (E) cells as a positive control. Results represent the mean+s.e. of three independent experiments the PVU1 and dl-141 mutations eliminate binding to all members of the pRb family (Brodsky and Pipas, 1998; Cole, 1996) . Since pRb is known to be phosphorylated in response to estrogen treatment, and since its role in regulating cell proliferation is well established, it is likely to be the major target of estrogen action. However, it would be interesting to determine if other pRb family members also contribute to estrogen/antiestrogen sensitivity in breast cancer cells.
SV-LT possesses additional functions that might contribute to antiestrogen resistance, including the ability to bind p300 and components of the basal transcription apparatus (Brodsky and Pipas, 1998; Cole, 1996) . It is possible that LT binding to components of the basal transcription apparatus plays a role in promoting antiestrogen resistance, since this function maps to N-terminal domains of SV-LT that are maintained in the T1-259 mutant (Damania and Alwine, 1996; Johnston et al., 1996) . We are not aware of any reports that Py-LT also binds to basal transcription factors, but it may do so. In contrast, the p300 binding activity of LT is unlikely to be involved in promoting antiestrogen resistance, since several reports indicate that C-terminal sequences that are missing in the T1-259 mutant are required for p300 binding by both SV-LT and Py-LT (Lill et al., 1997; Nemethova and Wintersberger, 1999) . As discussed previously, the p53 binding/inactivation function of SV-LT is not required to confer antiestrogen resistance, since it is missing in both the T1-259 and 2809 mutants, and in Py-LT.
It is interesting to compare the LT domains required to overcome cell cycle arrests in dierent systems. Expression of SV-LT can overcome a TGF-b1 mediated G 1 arrest in keratinocytes (Pietenpol et al., 1990) and mink lung epithelial cells (Laiho et al., 1990) , and this eect is dependent upon the pRbbinding domain. It is also probably independent of p53 binding, since the HPV E7 protein, which does not bind p53, has a similar eect (Laiho et al., 1990) . However, the absolute requirement for a pRb-binding domain, and the lack of a role for p53 binding, in promoting proliferation is not universal. For example, at least four independent functions of SV-LT, including pRb binding, p53 binding, and an unidenti®ed function abolished by the S189N mutation, contribute to its ability to promote proliferation in serum starved CV1P cells (Dickmanns et al., 1994; Dobbelstein et al., 1992) . Mutations in any one of these functions, including pRb binding, had little eect on LT's ability to promote proliferation in this system. In contrast, double mutants, including pRb binding/p53 binding double mutants, showed signi®cant defects. This variability in the requirements for pRb and/or p53 inactivation in overcoming cell cycle arrests may be due to dierences in the mechanisms by which treatments such as ICI, TGF-b1 and serum starvation induce cell cycle arrests, or may represent dierences in the requirements for pRb and/or p53 inactivation between cell lines.
We have considered the possibility that small T antigen (ST) plays a role in conferring antiestrogen resistance, since the SV-LT encoding vectors used in these experiments contain the entire early region of the viral genome, and therefore also encode ST. The PVU1 mutant encodes a wild type ST, yet it is completely defective in promoting proliferation in the presence of ICI. Thus, ST expression is not sucient to confer antiestrogen resistance. In addition, the CMVLT vector used to express Py-LT in transient transfections contains a LT cDNA, and does not encode ST. This plasmid confers ICI resistance to MCF-7 cells with the same eciency as SV-LT, indicating that ST expression is not required.
We attempted to determine whether LT expression confers antiestrogen resistance to MCF-7 cells in long term proliferation assays. Although overexpression of cyclin D1 conferred antiestrogen resistance to MCF-7 cells in short term assays, it was not sucient to promote the long term growth of these cells in the presence of antiestrogen (Pacilio et al., 1998) . Stably transfected cells expressing Py-LT were resistant to ICI treatment, as demonstrated by the facts that they contained cyclin A and hyperphosphorylated pRb, and synthesized DNA in the presence of ICI. However, this resistance was not complete. As shown in Figure 5b , both pRb phosphorylation and cyclin A protein levels were reduced somewhat by ICI treatment of WT1 and WT5 cells, although to a lesser extent than in the control WT4 or dl141 cells. Similar eects were seen on BrdUrd and [ 3 H]thymidine incorporation (data not shown), suggesting that proliferation of Py-LT expressing MCF-7 cells is not completely resistant to antiestrogen treatment. However, when the stably transfected cell lines were examined for Py-LT expression by immuno¯uorescence, only a subset of cells had detectable levels of LT, even during selective growth in G418 (data not shown). The apparent partial ICI-sensitivity seen in these experiments may therefore be due to variable expression of Py-LT in the transfected cells, rather than to an inability of LT to confer long term antiestrogen resistance.
Finally, the fact that both pRb inactivation and cyclin D1 overexpression promote antiestrogen resistance in MCF-7 cells suggests that deregulation of the pRb pathway might occur during the development of antiestrogen resistance in vivo. Several indirect pieces of evidence support this suggestion. Although 20 ± 25% of breast cancer cell lines examined lack functional pRb, all estrogen-responsive breast cancer cell lines identi®ed to date contain wild type pRb T'Ang et al., 1988) . In addition, in one study of primary breast cancers a signi®cant correlation was observed between the absence of pRb expression and a failure to respond to antiestrogen therapy (Anderson et al., 1996) . Together, these data suggest that hormone dependence cannot be maintained in the absence of pRb function, and that changes in pRb status or regulation could be involved in the progression of tumors to antiestrogen resistance.
Materials and methods
Cell culture
MCF-7 cells were obtained from Dr Michael Johnson (Lombardi Cancer Center) and were maintained in IMEM media (Bio¯uids Inc., Rockville, MD, USA) supplemented with 5% fetal bovine serum (Hyclone), penicillin (100 units/ ml) and streptomycin (100 mg/ml). To study the eects of estrogen and antiestrogens, cells were cultured in phenol red free IMEM supplemented with 5% charcoal stripped fetal bovine serum (Hyclone), with or without the addition of 0.2 nM 17b-estradiol (Sigma), 1 mM 4-hydroxytamoxifen (Sigma), or 100 nM ICI 182 780 (Zeneca Pharmaceuticals).
Antibodies and plasmids
The antibody to SV-LT was a supernatant of the L19 hybridoma cell line, which was a gift of Dr E Harlow (Harlow et al., 1981) . A rat monoclonal antibody, Ab-1 (Oncogene Science) was used to detect Py-LT by indirect immuno¯uorescence. A polyclonal rat antiserum was used for Py-LT immunoblotting, and was a gift of Dr Michele Fluck. Antibodies for pRb, cyclin A, and p53 were from Pharmingen. The mouse a-BrdUrd monoclonal antibody was obtained from Boehringer Mannheim, and sheep aBrdUrd was from Fitzgerald Industries, Concord, MA, USA. FITC conjugated goat a-rat, donkey a-sheep, and goat amouse antibodies were obtained from Sigma Biochemicals. Rhodamine Red-X conjugated donkey a-mouse antibody was from Jackson Immunoresearch.
The plasmids encoding wild type SV-LT, PVU1, and 2809 were obtained from Dr Charles Cole (Zhu and Cole, 1989; Zhu et al., 1991) . The SV40 genome in all of these plasmids contains a 6 bp deletion at the viral origin of replication that renders them replication incompetent (Gluzman et al., 1980; Keller and Alwine, 1984; Zhu et al., 1991) . The truncation mutant (T1 ± 259) was provided by Dr Ellen Fanning (Dobbelstein et al., 1992) . The T antigen encoded by this mutant lacks helicase and ATPase activity and will therefore not promote replication from the viral origin (Clark et al., 1983; Cole et al., 1986; Pipas et al., 1983) . The plasmid pCMVLT, which contains a cDNA encoding Py-LT, was obtained from Dr Brian Schahausen (Howes et al., 1996) . The pneoLT1 and dl-141-encoding vectors used for stable transfections were provided by Dr Michael Bastin (Larose et al., 1990 (Larose et al., , 1991 . The p53 dominant negative mutant (del239) was a gift of Dr John Minna (Takahashi et al., 1989) .
Transfections
For transient transfections, 5610
5 MCF-7 cells were plated in 60 mm tissue culture dishes containing 2 ± 18 mm cover slips and incubated at 378C overnight. Plasmid DNA was added to the cells using the Superfect reagent (Qiagen) following the protocol suggested by the manufacturer. SV40-LT transfections were done using 2.5 and 5 mg of DNA per dish, and pCMV-LT transfections were done using 0.3 mg DNA per dish. These amounts were chosen because they gave the highest transfection eciencies in pilot experiments. After 3 h, the transfection medium was removed and replaced with phenol red free IMEM supplemented with 5% charcoal stripped serum and 100 nM ICI 182 780. Cells were incubated for 43 h and then labeled with 25 mM 5-bromo-2'-deoxyuridine (BrdUrd) for 5 h. For control proliferating cultures, cells were grown in medium containing charcoal stripped serum supplemented with 0.2 nM 17b-estradiol. For stable transfections, 1 mg of DNA (pneoLT1 or dl141) was introduced into MCF7 cells using Lipofectin reagent (Gibco BRL). Colonies were selected for G418 resistance in medium containing 400 mg/ml G418 and expanded into clonal cell lines. Py-LT expression in these cell lines was assayed by Western blotting.
Indirect immunofluorescence
Forty-eight hours after transfection, cells on coverslips were ®xed with ice cold acetone/methanol (50 : 50 v/v), and washed with phosphate buered saline (PBS). The following procedures were used for antibody staining, with PBS washes (three times) being conducted between each treatment. Coverslips containing ®xed cells were incubated with a primary antibody against SV-LT or Py-LT for 45 min at 378C, then with the appropriate¯uorochrome-conjugated secondary antibody for 1 h at room temperature. Following this procedure, cells were re-®xed in a 50 mM glycine, 50% ethanol solution (pH 2.1) for 45 min at room temperature. Samples were then treated with 4 N HCl for 15 min to denature the DNA. The acid was aspirated, and coverslips were washed in PBS to neutral pH (7.0). Samples were then incubated with an appropriate anti-BrdUrd antibody (sheep for SV-LT and mouse for Py-LT) for 45 min at 378C, washed, and incubated with a second¯uorescent antibody (donkey anti-sheep FITC for SV-LT and donkey anti-mouse rhodamine Red X for Py-LT). Finally, the coverslips were extensively washed with PBS, mounted on glass slides, and viewed under a¯ourescence microscope (Olympus). The percentage of cells that were positive for LT (or p53) alone, BrdUrd alone, or both, were counted in each transfection. More than 100 LT-positive and 100 LT-negative cells were counted in each experiment. The images shown in Figure 2 were taken on a Meridian Instruments confocal microscope, and processed with Insight IQ computer software to generate single color and overlay images.
